AI In Cancer Diagnostics Market Size, Share & Trends Analysis Report By Component (Software Solutions, Hardware, Services), By Cancer Type, By End-user, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 2 Business Days
AI In Cancer Diagnostics Market Growth & Trends
The global AI in cancer diagnostics market size is expected to reach USD 996.1 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 28.0% from 2022 to 2030. Rising prevalence of cancer and growing demand for the early detection of the condition are some of the key factors driving the market.
Growing prevalence of cancer globally is expected to increase the demand for Artificial Intelligence (AI) in cancer diagnostics, thereby contributing to the market growth. According to data published by the American Cancer Society, 1.9 million new cases of cancer were diagnosed and more than 600,000 deaths occurred in 2021 in the U.S. Furthermore, increased number of hospitals and diagnostics centers incorporating AI/ML models for the early detection of the condition and increased adoption of digitalization at the hospitals are expected to be the key drivers for the market.
Increased demand to accurately and effectively diagnose cancer is expected to further increase the adoption of the technology for diagnosis. For instance, according to an article by the NCBI in April 2022, AI-assisted colonoscopy increased the adenoma detection rate to 29% as compared to conventional colonoscopy, which was about 20%. This is important as 1% increase in adenoma detection rate is associated with 3% decrease in colorectal cancer prevalence. AI allows the integration of a wide variety of streams such as genomics, EHR, radiographic images, pathology, and social networks to predict clinical decisions, which is expected to improve patient outcome.
Moreover, several governments have increased their healthcare IT expenditure, which is expected to improve healthcare infrastructure across different geographies. For instance, the healthcare IT spending of the U.S. government increased from 119.5 billion in 2020 to 176.5 billion in 2021. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis are expected to boost market growth. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients.
An increasing number of initiatives undertaken by the key players in the market along with the emergence of entrepreneurial startups that develop innovative solutions for AI in diagnostics is expected to drive the market. For instance, Xilis, a North Carolina-based startup, is working on the development of a precision oncology development platform for oncologists that helps to improve care outcomes for patients. Moreover, increased funding for these startups by the public and private players is expected to boost market growth.
AI In Cancer Diagnostics Market Report Highlights
AI In Cancer Diagnostics Market Growth & Trends
The global AI in cancer diagnostics market size is expected to reach USD 996.1 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 28.0% from 2022 to 2030. Rising prevalence of cancer and growing demand for the early detection of the condition are some of the key factors driving the market.
Growing prevalence of cancer globally is expected to increase the demand for Artificial Intelligence (AI) in cancer diagnostics, thereby contributing to the market growth. According to data published by the American Cancer Society, 1.9 million new cases of cancer were diagnosed and more than 600,000 deaths occurred in 2021 in the U.S. Furthermore, increased number of hospitals and diagnostics centers incorporating AI/ML models for the early detection of the condition and increased adoption of digitalization at the hospitals are expected to be the key drivers for the market.
Increased demand to accurately and effectively diagnose cancer is expected to further increase the adoption of the technology for diagnosis. For instance, according to an article by the NCBI in April 2022, AI-assisted colonoscopy increased the adenoma detection rate to 29% as compared to conventional colonoscopy, which was about 20%. This is important as 1% increase in adenoma detection rate is associated with 3% decrease in colorectal cancer prevalence. AI allows the integration of a wide variety of streams such as genomics, EHR, radiographic images, pathology, and social networks to predict clinical decisions, which is expected to improve patient outcome.
Moreover, several governments have increased their healthcare IT expenditure, which is expected to improve healthcare infrastructure across different geographies. For instance, the healthcare IT spending of the U.S. government increased from 119.5 billion in 2020 to 176.5 billion in 2021. Increasing initiatives undertaken by the government to increase the adoption of AI-assisted technologies for cancer diagnosis are expected to boost market growth. For instance, NITI Aayog, the public policy think tank of the Indian Government, aims to build an Imaging Biobank in association with the Department of Biotechnology, wherein it will create a database of cancer-related pathology and radiology images of more than 20,000 profiles of patients.
An increasing number of initiatives undertaken by the key players in the market along with the emergence of entrepreneurial startups that develop innovative solutions for AI in diagnostics is expected to drive the market. For instance, Xilis, a North Carolina-based startup, is working on the development of a precision oncology development platform for oncologists that helps to improve care outcomes for patients. Moreover, increased funding for these startups by the public and private players is expected to boost market growth.
AI In Cancer Diagnostics Market Report Highlights
- By component, in 2021, the software solutions segment held the largest share of over 40.0% due to the launch of innovative solutions that help in the early and accurate diagnosis of the condition
- In 2021, the others cancer type segment held the largest share of over 30.0%. The others segment includes cervical, bladder, liver, uterine, and skin cancer, among others. The higher prevalence of these conditions and the use of AI/ML algorithms for accurate diagnosis are some of the factors driving the segment
- In 2021, the hospitals segment held the largest share of over 55.0% owing to the increasing adoption of AI in order to reduce the diagnosis time
- In 2021, North America held the largest share of over 55.0% due to the availability of advanced healthcare facilities and high healthcare expenditure
CHAPTER 1 METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Research Methodology
1.3.1. Information Procurement
1.3.1.1. Purchased database
1.3.1.2. GVR’s internal database
1.3.2. Primary Research
1.4. Research Scope and Assumptions
1.5. List to Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.2. Market Outlook
2.3. Segment Outlook
2.4. Competitive Insights
2.5. AI in Cancer Diagnostics Market
CHAPTER 3. AI IN CANCER DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.2. Penetration and Growth Prospect Mapping
3.3. Market Dynamics
3.4. AI in Cancer Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.3. Impact of COVID-19 on the market
CHAPTER 4 AI IN CANCER DIAGNOSTICS MARKET: COMPONENT ESTIMATES & TREND ANALYSIS
4.1. Definitions & Scope
4.2. AI in Cancer Diagnostics Market: Component Movement Analysis, USD Million, 2021 & 2030
4.3. Software Solutions
4.3.1. Software Solutions market estimates and forecasts, 2017 - 2030 (USD Million)
4.4. Hardware
4.4.1. Hardware market estimates and forecasts, 2017 - 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 5 AI IN CANCER DIAGNOSTICS MARKET: CANCER TYPE ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. AI in Cancer Diagnostics Market: Cancer Type Movement Analysis, USD Million, 2021 & 2030
5.3. Breast Cancer
5.3.1. Breast Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.4. Lung Cancer
5.4.1. Lung Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.5. Prostate Cancer
5.5.1. Prostate Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.7. Brain Tumor
5.7.1. Brain Tumor market estimates and forecasts, 2017 - 2030 (USD Million)
5.8. Other
5.8.1. Other market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 6 AI IN CANCER DIAGNOSTICS MARKET: END-USER ESTIMATES & TREND ANALYSIS
6.1. Definitions & Scope
6.2. AI in Cancer Diagnostics Market: End-user Movement Analysis, USD Million, 2021 & 2030
6.3. Hospitals
6.3.1. Hospitals market estimates and forecasts, 2017 - 2030 (USD Million)
6.4. Surgical Centers and Medical Institutes
6.4.1. Surgical Centers and Medical Institutes market estimates and forecasts, 2017 - 2030 (USD Million)
6.5. Others
6.5.1. Others market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 AI IN CANCER DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Snapshot
7.2. AI in Cancer Diagnostics Market: Regional Movement Analysis
7.3. North America
7.3.1. North America market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.2. North America market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.3. North America market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.3.4. U.S.
7.3.4.1. U.S. market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.4.2. U.S. market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.4.3. U.S. market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.3.5. Canada
7.3.5.1. Canada market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.5.2. Canada market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.5.3. Canada market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.2. Europe market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.3. Europe market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.4. Germany
7.4.4.1. Germany market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.4.2. Germany market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.4.3. Germany market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.5. U.K.
7.4.5.1. U.K. market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.5.2. U.K. market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.5.3. U.K. market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.6. France
7.4.6.1. France market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.6.2. France market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.6.3. France market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.7. Italy
7.4.7.1. Italy market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.7.2. Italy market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.7.3. Italy market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.8. Spain
7.4.8.1. Spain market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.8.2. Spain market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.8.3. Spain market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.9. Russia
7.4.9.1. Russia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.9.2. Russia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.9.3. Russia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.2. Asia Pacific market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.3. Asia Pacific market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.4. Japan
7.5.4.1. Japan market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.4.2. Japan market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.4.3. Japan market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.5. China
7.5.5.1. China market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.5.2. China market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.5.3. China market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.6. India
7.5.6.1. India market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.6.2. India market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.6.3. India market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.7. Australia
7.5.7.1. Australia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.7.2. Australia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.7.3. Australia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.8. South Korea
7.5.8.1. South Korea market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.8.2. South Korea market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.8.3. South Korea market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.2. Latin America market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.3. Latin America market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.4. Brazil
7.6.4.1. Brazil market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.4.2. Brazil market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.4.3. Brazil market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.5. Mexico
7.6.5.1. Mexico market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.5.2. Mexico market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.5.3. Mexico market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.6. Argentina
7.6.6.1. Argentina market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.6.2. Argentina market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.6.3. Argentina market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7. MEA
7.7.1. MEA market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.2. MEA market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.3. MEA market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.4. South Africa
7.7.4.1. South Africa market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.4.2. South Africa market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.4.3. South Africa market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.5.2. Saudi Arabia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.5.3. Saudi Arabia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.6. UAE
7.7.6.1. UAE market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.6.2. UAE market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.6.3. UAE market estimates and forecasts, by end user 2017 - 2030 (USD Million)
CHAPTER 8. AI IN CANCER DIAGNOSTICS MARKET - COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Competition Categorization
8.3. Company Market Position Analysis
CHAPTER 9. COMPANY PROFILES
9.1. EarlySign
9.1.1. Company overview
9.1.2. Financial performance
9.1.3. Product benchmarking
9.1.4. Strategic initiatives
9.2. Cancer Center.ai
9.2.1. Company overview
9.2.2. Financial performance
9.2.3. Product benchmarking
9.2.4. Strategic initiatives
9.3. Microsoft
9.3.1. Company overview
9.3.2. Financial performance
9.3.3. Product benchmarking
9.3.4. Strategic initiatives
9.4. Flatiron
9.4.1. Company overview
9.4.2. Financial performance
9.4.3. Product benchmarking
9.4.4. Strategic initiatives
9.5. Path AI
9.5.1. Company overview
9.5.2. Financial performance
9.5.3. Product benchmarking
9.5.4. Strategic initiatives
9.6. Therapixel
9.6.1. Company overview
9.6.2. Financial performance
9.6.3. Product benchmarking
9.6.4. Strategic initiatives
9.7. Tempus
9.7.1. Company overview
9.7.2. Financial performance
9.7.3. Product benchmarking
9.7.4. Strategic initiatives
9.8. Paige AI Inc.
9.8.1. Company overview
9.8.2. Financial performance
9.8.3. Product benchmarking
9.8.4. Strategic initiatives
9.9. Kheiron Medical Technologies Limited
9.9.1. Company overview
9.9.2. Financial performance
9.9.3. Product benchmarking
9.9.4. Strategic initiatives
9.10. SkinVision
9.10.1. Company overview
9.10.2. Financial performance
9.10.3. Product benchmarking
9.10.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Market Definition
1.3. Research Methodology
1.3.1. Information Procurement
1.3.1.1. Purchased database
1.3.1.2. GVR’s internal database
1.3.2. Primary Research
1.4. Research Scope and Assumptions
1.5. List to Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.2. Market Outlook
2.3. Segment Outlook
2.4. Competitive Insights
2.5. AI in Cancer Diagnostics Market
CHAPTER 3. AI IN CANCER DIAGNOSTICS MARKET VARIABLES, TRENDS, & SCOPE
3.2. Penetration and Growth Prospect Mapping
3.3. Market Dynamics
3.4. AI in Cancer Diagnostics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.3. Impact of COVID-19 on the market
CHAPTER 4 AI IN CANCER DIAGNOSTICS MARKET: COMPONENT ESTIMATES & TREND ANALYSIS
4.1. Definitions & Scope
4.2. AI in Cancer Diagnostics Market: Component Movement Analysis, USD Million, 2021 & 2030
4.3. Software Solutions
4.3.1. Software Solutions market estimates and forecasts, 2017 - 2030 (USD Million)
4.4. Hardware
4.4.1. Hardware market estimates and forecasts, 2017 - 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 5 AI IN CANCER DIAGNOSTICS MARKET: CANCER TYPE ESTIMATES & TREND ANALYSIS
5.1. Definitions and Scope
5.2. AI in Cancer Diagnostics Market: Cancer Type Movement Analysis, USD Million, 2021 & 2030
5.3. Breast Cancer
5.3.1. Breast Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.4. Lung Cancer
5.4.1. Lung Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.5. Prostate Cancer
5.5.1. Prostate Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.6. Colorectal Cancer
5.6.1. Colorectal Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
5.7. Brain Tumor
5.7.1. Brain Tumor market estimates and forecasts, 2017 - 2030 (USD Million)
5.8. Other
5.8.1. Other market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 6 AI IN CANCER DIAGNOSTICS MARKET: END-USER ESTIMATES & TREND ANALYSIS
6.1. Definitions & Scope
6.2. AI in Cancer Diagnostics Market: End-user Movement Analysis, USD Million, 2021 & 2030
6.3. Hospitals
6.3.1. Hospitals market estimates and forecasts, 2017 - 2030 (USD Million)
6.4. Surgical Centers and Medical Institutes
6.4.1. Surgical Centers and Medical Institutes market estimates and forecasts, 2017 - 2030 (USD Million)
6.5. Others
6.5.1. Others market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 AI IN CANCER DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Snapshot
7.2. AI in Cancer Diagnostics Market: Regional Movement Analysis
7.3. North America
7.3.1. North America market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.2. North America market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.3. North America market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.3.4. U.S.
7.3.4.1. U.S. market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.4.2. U.S. market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.4.3. U.S. market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.3.5. Canada
7.3.5.1. Canada market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.3.5.2. Canada market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.3.5.3. Canada market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4. Europe
7.4.1. Europe market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.2. Europe market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.3. Europe market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.4. Germany
7.4.4.1. Germany market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.4.2. Germany market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.4.3. Germany market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.5. U.K.
7.4.5.1. U.K. market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.5.2. U.K. market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.5.3. U.K. market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.6. France
7.4.6.1. France market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.6.2. France market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.6.3. France market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.7. Italy
7.4.7.1. Italy market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.7.2. Italy market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.7.3. Italy market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.8. Spain
7.4.8.1. Spain market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.8.2. Spain market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.8.3. Spain market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.4.9. Russia
7.4.9.1. Russia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.4.9.2. Russia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.4.9.3. Russia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Asia Pacific market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.2. Asia Pacific market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.3. Asia Pacific market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.4. Japan
7.5.4.1. Japan market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.4.2. Japan market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.4.3. Japan market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.5. China
7.5.5.1. China market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.5.2. China market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.5.3. China market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.6. India
7.5.6.1. India market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.6.2. India market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.6.3. India market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.7. Australia
7.5.7.1. Australia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.7.2. Australia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.7.3. Australia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.5.8. South Korea
7.5.8.1. South Korea market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.5.8.2. South Korea market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.5.8.3. South Korea market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6. Latin America
7.6.1. Latin America market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.2. Latin America market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.3. Latin America market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.4. Brazil
7.6.4.1. Brazil market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.4.2. Brazil market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.4.3. Brazil market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.5. Mexico
7.6.5.1. Mexico market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.5.2. Mexico market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.5.3. Mexico market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.6.6. Argentina
7.6.6.1. Argentina market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.6.6.2. Argentina market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.6.6.3. Argentina market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7. MEA
7.7.1. MEA market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.2. MEA market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.3. MEA market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.4. South Africa
7.7.4.1. South Africa market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.4.2. South Africa market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.4.3. South Africa market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.5.2. Saudi Arabia market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.5.3. Saudi Arabia market estimates and forecasts, by end user 2017 - 2030 (USD Million)
7.7.6. UAE
7.7.6.1. UAE market estimates and forecasts, by component 2017 - 2030 (USD Million)
7.7.6.2. UAE market estimates and forecasts, by cancer type 2017 - 2030 (USD Million)
7.7.6.3. UAE market estimates and forecasts, by end user 2017 - 2030 (USD Million)
CHAPTER 8. AI IN CANCER DIAGNOSTICS MARKET - COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Competition Categorization
8.3. Company Market Position Analysis
CHAPTER 9. COMPANY PROFILES
9.1. EarlySign
9.1.1. Company overview
9.1.2. Financial performance
9.1.3. Product benchmarking
9.1.4. Strategic initiatives
9.2. Cancer Center.ai
9.2.1. Company overview
9.2.2. Financial performance
9.2.3. Product benchmarking
9.2.4. Strategic initiatives
9.3. Microsoft
9.3.1. Company overview
9.3.2. Financial performance
9.3.3. Product benchmarking
9.3.4. Strategic initiatives
9.4. Flatiron
9.4.1. Company overview
9.4.2. Financial performance
9.4.3. Product benchmarking
9.4.4. Strategic initiatives
9.5. Path AI
9.5.1. Company overview
9.5.2. Financial performance
9.5.3. Product benchmarking
9.5.4. Strategic initiatives
9.6. Therapixel
9.6.1. Company overview
9.6.2. Financial performance
9.6.3. Product benchmarking
9.6.4. Strategic initiatives
9.7. Tempus
9.7.1. Company overview
9.7.2. Financial performance
9.7.3. Product benchmarking
9.7.4. Strategic initiatives
9.8. Paige AI Inc.
9.8.1. Company overview
9.8.2. Financial performance
9.8.3. Product benchmarking
9.8.4. Strategic initiatives
9.9. Kheiron Medical Technologies Limited
9.9.1. Company overview
9.9.2. Financial performance
9.9.3. Product benchmarking
9.9.4. Strategic initiatives
9.10. SkinVision
9.10.1. Company overview
9.10.2. Financial performance
9.10.3. Product benchmarking
9.10.4. Strategic initiatives
LIST OF TABLES
Table 1 Factors used in segment share estimation
Table 2 List of secondary data sources
Table 3 Primary interview details, by source
Table 4 Primary interview details, by region
Table 5 North America market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 6 North America market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 7 North America market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 8 North America market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 9 U.S. market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 10 U.S. market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 11 U.S. market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 12 Canada market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 13 Canada market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 14 Canada market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 15 Europe market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 16 Europe market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 17 Europe market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 18 Europe market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 19 Germany market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 20 Germany market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 21 Germany market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 22 U.K. market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 23 U.K. market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 24 U.K. market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 25 France market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 26 France market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 27 Italy market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 28 Italy market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 29 Italy market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 30 Spain market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 31 Spain market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 32 Spain market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 33 Russia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 34 Russia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 35 Russia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 36 Asia Pacific market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 37 Asia Pacific market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 38 Asia Pacific market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 39 Asia Pacific market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 40 Japan market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 41 Japan market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 42 Japan market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 43 China market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 44 China market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 45 China market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 46 India market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 47 India market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 48 India market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 49 Australia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 50 Australia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 51 Australia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 52 South Korea market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 53 South Korea market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 54 South Korea market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 55 Latin America market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 56 Latin America market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 57 Latin America market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 58 Latin America market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 59 Brazil market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 60 Brazil market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 61 Brazil market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 62 Mexico market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 63 Mexico market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 64 Mexico market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 65 Argentina market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 66 Argentina market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 67 Argentina market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 68 MEA market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 69 MEA market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 70 MEA market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 71 MEA market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 72 South Africa market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 73 South Africa market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 74 South Africa market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 75 Saudi Arabia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 76 Saudi Arabia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 77 Saudi Arabia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 78 UAE market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 79 UAE market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 80 UAE market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 1 Factors used in segment share estimation
Table 2 List of secondary data sources
Table 3 Primary interview details, by source
Table 4 Primary interview details, by region
Table 5 North America market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 6 North America market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 7 North America market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 8 North America market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 9 U.S. market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 10 U.S. market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 11 U.S. market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 12 Canada market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 13 Canada market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 14 Canada market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 15 Europe market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 16 Europe market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 17 Europe market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 18 Europe market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 19 Germany market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 20 Germany market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 21 Germany market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 22 U.K. market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 23 U.K. market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 24 U.K. market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 25 France market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 26 France market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 27 Italy market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 28 Italy market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 29 Italy market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 30 Spain market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 31 Spain market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 32 Spain market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 33 Russia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 34 Russia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 35 Russia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 36 Asia Pacific market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 37 Asia Pacific market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 38 Asia Pacific market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 39 Asia Pacific market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 40 Japan market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 41 Japan market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 42 Japan market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 43 China market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 44 China market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 45 China market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 46 India market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 47 India market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 48 India market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 49 Australia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 50 Australia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 51 Australia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 52 South Korea market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 53 South Korea market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 54 South Korea market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 55 Latin America market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 56 Latin America market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 57 Latin America market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 58 Latin America market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 59 Brazil market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 60 Brazil market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 61 Brazil market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 62 Mexico market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 63 Mexico market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 64 Mexico market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 65 Argentina market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 66 Argentina market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 67 Argentina market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 68 MEA market estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 69 MEA market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 70 MEA market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 71 MEA market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 72 South Africa market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 73 South Africa market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 74 South Africa market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 75 Saudi Arabia market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 76 Saudi Arabia market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 77 Saudi Arabia market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
Table 78 UAE market estimates and forecasts, by component, 2017 - 2030 (USD Million)
Table 79 UAE market estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 80 UAE market estimates and forecasts, by end user, 2017 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market Snapshot
Fig. 9 AI in Cancer Diagnostics Market variables, trends & scope
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Company/Competition Categorization
Fig. 14 Company market position analysis
Fig. 15 Component market share analysis, 2021 & 2030
Fig. 16 Segment Dashboard
Fig. 17 Software Solutions market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 18 Hardware market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 19 Services market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 20 Cancer Type market share analysis, 2021 & 2030
Fig. 21 Segment Dashboard
Fig. 22 Breast Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 23 Lung Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 24 Prostate Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 25 Colorectal Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 26 Brain Tumor market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 27 Other market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 28 End-user market share analysis, 2021 & 2030
Fig. 29 Segment Dashboard
Fig. 30 Hospital market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 31 Surgical Centers and Medical Institutes market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 32 Others market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 33 Regional market place: Key takeaways
Fig. 34 AI in Cancer Diagnostics Market: Regional outlook, 2021 & 2030 (USD Million)
Fig. 35 North America market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 36 U.S. market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 37 Canada market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 38 Europe market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 39 Germany market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 40 U.K. market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 41 France market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 42 Italy market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 43 Spain market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 44 Russia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 45 Asia Pacific market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 46 Japan market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 47 China market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 48 India market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 49 Australia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 50 South Korea market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 51 Latin America market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 52 Brazil market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 53 Mexico market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 54 Argentina market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 55 MEA market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 56 South Africa market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 57 Saudi Arabia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 58 UAE market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data Triangulation Techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market Snapshot
Fig. 9 AI in Cancer Diagnostics Market variables, trends & scope
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Company/Competition Categorization
Fig. 14 Company market position analysis
Fig. 15 Component market share analysis, 2021 & 2030
Fig. 16 Segment Dashboard
Fig. 17 Software Solutions market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 18 Hardware market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 19 Services market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 20 Cancer Type market share analysis, 2021 & 2030
Fig. 21 Segment Dashboard
Fig. 22 Breast Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 23 Lung Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 24 Prostate Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 25 Colorectal Cancer market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 26 Brain Tumor market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 27 Other market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 28 End-user market share analysis, 2021 & 2030
Fig. 29 Segment Dashboard
Fig. 30 Hospital market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 31 Surgical Centers and Medical Institutes market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 32 Others market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 33 Regional market place: Key takeaways
Fig. 34 AI in Cancer Diagnostics Market: Regional outlook, 2021 & 2030 (USD Million)
Fig. 35 North America market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 36 U.S. market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 37 Canada market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 38 Europe market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 39 Germany market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 40 U.K. market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 41 France market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 42 Italy market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 43 Spain market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 44 Russia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 45 Asia Pacific market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 46 Japan market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 47 China market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 48 India market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 49 Australia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 50 South Korea market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 51 Latin America market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 52 Brazil market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 53 Mexico market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 54 Argentina market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 55 MEA market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 56 South Africa market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 57 Saudi Arabia market revenue estimates and forecasts, 2017 - 2030 (USD Million)
Fig. 58 UAE market revenue estimates and forecasts, 2017 - 2030 (USD Million)
